Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
enGene Holdings ( (ENGN) ) has issued an announcement.
enGene Holdings has been recognized by BioSpace as one of the 2026 Best Places to Work, highlighting its commitment to innovation and a collaborative work culture. This accolade, following its 2025 Biotech Company of the Year award from BIOTECanada, underscores enGene’s industry leadership and the potential impact of its non-viral gene therapy, detalimogene voraplasmid, which is currently in Phase 2 trials for high-risk bladder cancer. The recognition enhances enGene’s reputation in the life sciences recruitment market, emphasizing its focus on patient-first values and its strategic position in addressing unmet medical needs in bladder cancer treatment.
The most recent analyst rating on (ENGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage company specializing in non-viral genetic medicines, focusing on developing therapies for urological cancers. The company is known for its innovative Dually Derivatized Oligochitosan (DDX) platform, which aims to transform gene therapy accessibility and utilization.
Average Trading Volume: 257,871
Technical Sentiment Signal: Buy
Current Market Cap: $354.2M
Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.